Vikas Jain

Dr. Vikas Jain

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
VJVikas Jain
Vikas Jain
HKHitesh Kumar
Hitesh Kumar
HAHaritha V. Anod
Haritha V. Anod
PCPallavi Chand
Pallavi Chand
NGN. Vishal Gupta
N. Vishal Gupta
Siddharth S. KesharwaniSiddharth S. Kesharwani
Siddharth S. Kesharwani

13 February 2023 in Journal of Advanced Research
Verified
Journal Article
Open access
HKHitesh Kumar
Hitesh Kumar
NGN. Vishal Gupta
N. Vishal Gupta
RJRupshee Jain
Rupshee Jain
SMSubbaRao V. Madhunapantula
SubbaRao V. Madhunapantula
CBC. Saravana Babu
C. Saravana Babu
VJVikas Jain
Vikas Jain
Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive phenotype of breast cancer with associated chemoresistance. The development of chemo- or radioresistance could be attributed to diverse tumor microenvironments, overexpression of membrane proteins (transporters), epigenetic changes, and alteration of the cell signaling pathways/genes associated with the development of cancer stem cells (CSCs). Due to the diverse and heterogeneous nature of TNBC, therapeutic response to the existing modalities offers limited scope and thus results in reccurance after therapy. To establish landmark therapeutic efficacy, a number of novel therapeutic modalities have been proposed. In addition, reversal of the resistance that developed during treatment may be altered by employing appropriate therapeutic modalities. This review aims to discuss the plethora of investigations carried out, which will help readers understand and make an appropriate choice of therapy directed toward complete elimination of TNBC. This manuscript addresses the major contributory factors from the tumor microenvironment that are responsible for the development of chemoresistance and poor prognosis. The associated cellular events and molecular mechanism-based therapeutic interventions have been explained in detail. Inhibition of ABC transporters, cell signaling pathways associated with CSCs, and epigenetic modification offers promising results in this regard. TNBC progression, invasion, metastasis and recurrence can also be inhibited by blocking multiple cell signaling pathways, targeting specific receptors/epigenetic targets, disrupting bioenergetics and generating reactive oxygen species (ROS).

1 October 2012 in Biomaterials
Verified
Journal Article
Closed access
VJVikas Jain
Vikas Jain
NSNitin K. Swarnakar
Nitin K. Swarnakar
PMPrabhat R. Mishra
Prabhat R. Mishra
AVAshwni Verma
Ashwni Verma
AKAnkur Kaul
Ankur Kaul
NJNarendra K. Jain
Narendra K. Jain

1 August 2010 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
VDVaibhav Dubey
Vaibhav Dubey
DMDinesh Kumar Mishra
Dinesh Kumar Mishra
MNManoj Nahar
Manoj Nahar
VJVikas Jain
Vikas Jain
NJNarendra Kumar Jain
Narendra Kumar Jain

8 September 2007 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
NSNitin K. Swarnakar
Nitin K. Swarnakar
VJVikas Jain
Vikas Jain
VDVaibhav Dubey
Vaibhav Dubey
DMDinesh Kumar Mishra
Dinesh Kumar Mishra
NJN.K. Jain
N.K. Jain

28 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RKRachna M. Kumar
Rachna M. Kumar
HKHitesh Kumar
Hitesh Kumar
TBTanvi Bhatt
Tanvi Bhatt
RJRupshee Jain
Rupshee Jain
KPKanan Panchal
Kanan Panchal
VJVikas Jain
Vikas Jain
Cancer is one of the major causes of mortality, globally. Cancerous cells invade normal cells and metastasize to distant sites with the help of the lymphatic system. There are several mechanisms involved in the development and progression of cancer. Several treatment strategies including the use of phytoconstituents have evolved and been practiced for better therapeutic outcomes against cancer. Fisetin is one such naturally derived flavone that offers numerous pharmacological benefits, i.e., antioxidant, anti-inflammatory, antiangiogenic, and anticancer properties. It inhibits the rapid growth, invasiveness, and metastasis of tumors by hindering the multiplication of cancer cells, and prompts apoptosis by avoiding cell division related to actuation of caspase-9 and caspase-8. However, its poor bioavailability associated with its extreme hydrophobicity hampers its clinical utility. The issues related to fisetin delivery can be addressed by adapting to the developmental aspects of nanomedicines, such as formulating it into lipid or polymer-based systems, including nanocochleates and liposomes. This review aims to provide in-depth information regarding fisetin as a potential candidate for anticancer therapy, its properties and various formulation strategies.